Bayer to Pay $40M Settlement for Alleged Kickbacks, False Claims Bayer to Pay $40M Settlement for Alleged Kickbacks, False Claims
The settlement resolves allegations of kickbacks and false claims involving aprotinin, cerivastatin, and moxifloxacin that came from two whistleblower lawsuits.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 7, 2022 Category: Cardiology Tags: Cardiology News Source Type: news

Africa: Major Improvements in Quality of Life for People With Drug-Susceptible TB Expected Following Updates in TB Treatment Regimens
[WHO] Landmark changes in shortening treatment duration has been announced by WHO in its updated consolidated guidelines on treatment of drug-susceptible TB. The guidelines include a new recommendation for the use of a 4-month regimen composed of isoniazid, rifapentine, moxifloxacin and pyrazinamide for the treatment and care of DS-TB. The shorter and effective new regimen offers improved quality of life for people with TB. (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - May 30, 2022 Category: Infectious Diseases Source Type: news

Aurobindo, Sun Pharma recall products in US market
According to the latest enforcement report issued by the US Food and Drug Administration (USFDA), the US-based arm of Aurobindo Pharma is recalling 1,15,776 bottles of Moxifloxacin Ophthalmic Solution, an antibiotic used in the treatment of bacterial infections. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 27, 2022 Category: Pharmaceuticals Source Type: news

Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022
This report describes a recommendation for using a 4-month regimen for the treatment of drug-susceptible pulmonary tuberculosis. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - February 24, 2022 Category: American Health Tags: Healthy Living MMWR Morbidity & Mortality Weekly Report Tuberculosis (TB) Tuberculosis Vaccine (BCG) Source Type: news

Antimicrobial prescribing: delafloxacin for community-acquired pneumonia Evidence Summary [ES37], NICE (published 10th August 2021)
Review of delafloxacin, a fluoroquinolone antibiotic available as an injection or tablet, covers the strengths and limitations of the efficacy and safety data from the pivotal RCT, where it was found to be non-inferior to moxifloxacin for community-acquired bacterial pneumonia (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 12, 2021 Category: Consumer Health News Source Type: news

Four-Month Rifapentine Regimen With Moxifloxacin Noninferior for TB
THURSDAY, May 6, 2021 -- A four-month rifapentine-based regimen containing moxifloxacin is noninferior to a standard six-month regimen for treatment of tuberculosis, according to a study published in the May 6 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2021 Category: Pharmaceuticals Source Type: news

Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study, Clinical Infectious Diseases 72(5): 836-844
Conclusions C. difficile infection risk increases with antibiotic duration, and there are wide disparities in risks associated with antibiotic courses used for similar indications. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 17, 2021 Category: Consumer Health News Source Type: news

Association between Antibiotic Consumption and Incidence of Clostridioides difficile Infection in a Hospital. Journal of Korean medical science 35(47): e407
Previous exposure to antimicrobials is a major risk factor for Clostridioides difficile infection (CDI). Antibiotic prescription and C. difficile toxin assay records of patients admitted to a tertiary hospital in Korea from 2009 to 2013 were collected to investigate the association between antibiotic consumption and CDI incidence. A Spearman ' s correlation analysis between CDI incidence (positive result of toxin assay/10,000 admissions) and antibiotic consumption (defined daily dose/1,000 patient-days) was performed on a monthly basis. Using the matched month approach, we found a significant correlation between CDI rate a...
Source: Current Awareness Service for Health (CASH) - January 15, 2021 Category: Consumer Health News Source Type: news

moxifloxacin (Avelox)
Title: moxifloxacin (Avelox)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 8/14/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 14, 2019 Category: Drugs & Pharmacology Source Type: news

Omadacycline Noninferior to Moxifloxacin for Pneumonia
WEDNESDAY, Feb. 6, 2019 -- Omadacycline is noninferior to moxifloxacin for community-acquired bacterial pneumonia and noninferior to linezolid for acute bacterial skin infections, according to two studies published in the Feb. 7 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 6, 2019 Category: Pharmaceuticals Source Type: news

Moxeza (Moxifloxacin Hydrochloride Ophthalmic Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 5, 2017 Category: Drugs & Pharmacology Source Type: news

Four - Month Rifapentine Regimen With Moxifloxacin Noninferior for TB
Rifapentine - based regimen with moxifloxacin noninferior to six - month control regimen of rifampin, isoniazid, pyrazinamide, ethambutol (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 12, 2017 Category: Respiratory Medicine Tags: Infections, Pharmacy, Pulmonology, Journal, Source Type: news

Mylan Launches First AP-rated Generic Avelox(R) Injection
HERTFORDSHIRE, England and PITTSBURGH, Oct. 5, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Moxifloxacin Hydrochloride in 0.8% Sodium Chloride Injection, 400 mg/250 mL (1.6 mg/mL) in 2... Biopharmaceuticals, Product Launch Mylan, Moxifloxacin, Avelox, fluoroquinolone, antibacterial (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 5, 2017 Category: Pharmaceuticals Source Type: news

Tuberculosis drug may work better than others in its class
(PLOS) Treatment of tuberculosis involves a combination of several drugs, sometimes including drugs from a class known as fluoroquinolones. Using computer simulations, scientists have shown that the fluoroquinolone known as moxifloxacin may be superior to two other commonly used fluoroquinolones, according to a new paper in PLOS Computational Biology. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 17, 2017 Category: Infectious Diseases Source Type: news

FDA Warns About Triamcinolone and Moxifloxacin Combo for Eye FDA Warns About Triamcinolone and Moxifloxacin Combo for Eye
The FDA issued a safety alert after serious adverse events were reported in at least 43 patients who received a compounded triamcinolone and moxifloxacin product by intravitreal injection.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 28, 2017 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news